NASDAQ:PRQR ProQR Therapeutics Q2 2025 Earnings Results & Report $1.38 +0.13 (+9.92%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more. ProQR Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.14 versus the -$0.08 consensus estimate, while revenue of $4.33 million fell short of the $5.01 million estimate by $677.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeBefore Market OpensConference Call9:30 AM ET ProQR Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.08Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersProQR Therapeutics Revenue ResultsActual Revenue$4.33 millionExpected Revenue$5.01 millionBeat/MissMissed by -$677.00 thousandYoY Revenue GrowthN/AUpcoming EarningsProQR Therapeutics' Q4 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) ProQR Therapeutics Q2 2025 Earnings FAQ Did ProQR Therapeutics beat earnings estimates for Q2 2025? ProQR Therapeutics (NASDAQ:PRQR) reported earnings of -$0.14 per share for Q2 2025, missing the consensus estimate of -$0.08. The report was announced on Thursday, August 7, 2025. What was ProQR Therapeutics' revenue for Q2 2025? ProQR Therapeutics reported revenue of $4.33 million for Q2 2025, against a consensus estimate of $5.01 million. When is ProQR Therapeutics' next earnings date? ProQR Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for ProQR Therapeutics on the company's earnings history page. ProQR Therapeutics Earnings HeadlinesProQR Announces Third Quarter 2026 Operating and Financial ResultsNovember 12 at 7:00 AM | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesNovember 12 at 2:15 AM | americanbankingnews.comA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 12 at 1:00 AM | Concord Gold Capital (Ad)ProQR Therapeutics N.V. (PRQR)November 11 at 9:58 AM | finance.yahoo.comProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesOctober 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)October 2, 2026 | theglobeandmail.comSee More ProQR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email. Email Address About ProQR TherapeuticsProQR Therapeutics (NASDAQ:PRQR) is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations. The company was founded by Daniel de Boer, who has served as its chief executive officer and has led its efforts to develop RNA-based medicines.View ProQR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
